AbbVie

Open: 137.3 Close: 135.92 Change: -1.38

You're losing the opportunity of using an AI to get informed about AbbVie.

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, increase, stock, Dividend, dividend, year, positive, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

Wall Street analysts forecast ABBV stock price to rise over the next 12 months. Board of directors has increased its dividend by 270 percent since inception.

Today's News

AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. DoH, M42 and Abbvie partner for personalised medicines in Abu Dhabi. AbbVie Inc. (abbv) stock price, quote & news - stock analysis. In 2022, Abbvies revenue was $58.05 billion, an increase of 3.30% compared to the previous years $56.20 billion. Analyst Consensus: Buy Stock Forecasts: Buy stock Forecasts. AbbVie (ABBV) has recently been on Zacks.coms list of the most searched stocks. Boehringer Ingelheims biosimilar of Abbvie Incs. blockbuster arthritis drug Humira will be included in the reimbursement list of UnitedHealth Group Incs (UNH.N) OptumRx. Abbvie Inc is Overvalued by 10% compared to the current market price of 135.92 USD. Wall Street analysts forecast ABBV stock price to rise over the next 12 months. AbbV offers its products in various therapeutic categories. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. European Medicines Agencies Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of atogepant for the prophylaxis. AbbVie secures positive chmp opinion for atogepant for the preventive treatment of adults with migraine. European Medicines Agencies Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of atogeypant. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. Board of directors has increased its dividend by 270 percent since inception in 2013. European Medicines Agencies Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion. AbbVie Inc. per Employee $1.135M P/E Ratio 32.01 EPS $4.25 Yield 4.36% Dividend $1.48 Ex-Dividend Date Jul 13, 2023 Short Interest 11.38M 05/31/23 % of Float Shorted 0.65% Average Volume 5.46M. AbbVie to present at Goldman Sachs 44th Annual Global Healthcare Conference on June 14, 2023. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine. AbbVie announces Provincial Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, increase, stock, Dividend, dividend, year, positive, and the most common words in the summary are: abbvie, stock, market, news, health, abbv, top, . One of the sentences in the summary was: Board of directors has increased its dividend by 270 percent since inception.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #market #news #health #abbv #top.